January 18, 2026 - 10:04

U.S. regulators have granted Tesla a five-week extension to address allegations concerning its self-driving technology. The investigation focuses on claims that Tesla vehicles have violated traffic laws while operating in the company's "full self-driving" mode. This decision allows Tesla additional time to prepare its response to the concerns raised by authorities.
The extension comes amid increasing scrutiny of autonomous vehicle technologies and their safety implications. Regulators are particularly interested in understanding how Tesla's self-driving system interacts with existing traffic laws and whether it poses any risks to public safety. Tesla has been at the forefront of the electric vehicle market, and its self-driving capabilities have garnered both praise and criticism.
As the deadline approaches, industry experts are closely monitoring the situation, speculating on how Tesla's response may influence public perception and regulatory actions in the rapidly evolving landscape of autonomous driving. The outcome of this investigation could have significant implications for Tesla's future operations and the broader self-driving vehicle market.
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...